Table 2.
The ADMET predictions of the selected ligands: compounds A, B, and C.
ADMET | Compound A | Compound B | Compound C |
---|---|---|---|
Absorption | Remark (Probablity) | Remark (Probablity) | Remark (Probablity) |
Human Intestinal Absorption (HIA) | Good (0.99) | Good (0.91) | Good (0.96) |
Human oral bioavailability (HOB) | Good (0.76) | Safe (0.63) | Safe (0.79) |
Caco-2 permeability | Good (0.91) | Good (0.60) | Good (0.65) |
Distribution | |||
Plasma protein binding | Good (0.77) | Good (0.97) | Good (0.89) |
BBB permeant | Yes | Yes | Yes |
P-glycoprotein (P-gp) substrate | No | No | No |
Metabolism | |||
Cytochrome (CYP450) | |||
CYP1A2 inhibitor | Yes | Yes | No |
CYP2C19 inhibitor | No | No | No |
CYP2C9 inhibitor | No | No | No |
CYP2D6 inhibitor | No | No | No |
CYP3A4 inhibitor | No | No | No |
Excretion | |||
No info available | – | – | – |
Toxicity | |||
Organ Toxicity | |||
Human ether-a-go-go inhibition | Safe (0.71) | Safe (0.73) | Safe (0.79) |
Acute Oral Toxicity class III | Slightly toxic (0.74) | Slightly toxic (0.60) | Slightly toxic (0.42) |
Eye irritation | Irritating (0.97) | Irritating (0.86) | Irritating (0.95) |
Genomic Toxicity | |||
Carcinogenicity | Safe (0.80) | Safe (0.70) | Safe (0.61) |
Ames mutagenesis | Caution (0.51) | Safe (0.73) | Safe (0.64) |
Eco-Toxicity | |||
Biodegradation | Safe (0.78) | Safe (0.85) | Safe (0.55) |